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Differential Antibacterial Activity Against Pseudomonas
aeruginosa by Carbon Monoxide-Releasing Molecules
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Erick Denamur,5 Sian H. Crook,6 Brian E. Mann,6 David Scapens,6 Philippe Montravers,2
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Abstract
Aims: Carbon monoxide (CO) delivered in a controlled manner to cells and organisms mediates a variety of
pharmacological effects to the extent that CO-releasing molecules (CO-RMs) are being developed for therapeutic
purposes. Recently, ruthenium-based CO-RMs have been shown to posses important bactericidal activity.
Here we assessed the effect of fast CO releasers containing ruthenium (Ru(CO)3Cl(glycinate) [CORM-3] and
tricarbonyldichlororuthenium(II) dimer [CORM-2]) and a novel slow manganese-based CO releaser ([Me4N]
[Mn(CO)4(thioacetate)2] [CORM-371]) on O2 consumption and growth of Pseudomonas aeruginosa (PAO1). We
then compared these effects with the action elicited by sodium boranocarbonate (CORM-A1), which lacks a
transition metal but liberates CO with a rate similar to CORM-371. Results: CORM-2, CORM-3, and, to a lesser
extent, CORM-371 exerted a significant bactericidal effect and decreased O2 consumption in PAO1 in vitro. The
effect appeared to be independent of reactive oxygen species production, but in the case of metal-containing
compounds it was prevented by the thiol donor N-acetylcysteine. In contrast, CORM-A1 was bacteriostatic
rather than bactericidal in vitro eliciting only a moderate and transient decrease in O2 consumption. Innovation:
None of the tested CO-RMs was toxic to murine macrophages or human fibroblasts at the concentration im-
pairing PA01 growth but only ruthenium-containing CO-RMs showed potential therapeutic properties by in-
creasing the survival of mice infected with PA01. Conclusion: CO carriers inhibit bacterial growth and O2
consumption in vitro, but transition metal carbonyls appear more powerful than compounds spontaneously
liberating CO. The nature of the metal in CO-RMs also modulates the anti-bacterial effect, with ruthenium-based
CO-RMs being efficacious both in vitro and in vivo. Antioxid. Redox Signal. 16, 153–163.
Introduction
Carbon monoxide (CO) is a stable gas that occurs in na-ture as a product of incomplete oxidation or combustion
of organic matter. It is perceived as a highly toxic pollutant
although small quantities of this gas are produced endoge-
nously in plants, bacteria, and animals through heme me-
tabolism by heme oxygenase enzymes, which serve to
detoxify cells from harmful chemicals and protect against
oxidative stress (31, 10, 43, 8). The finding that CO interacts
effectively with several intracellular heme-containing targets
(i.e., soluble guanylate cyclase, cytochrome c oxidase,
NADPH oxidase, and BK potassium channels) to transduce
important cellular signals has intensified the investigation on
the biological properties of this gaseous molecule (6). Indeed,
it has been demonstrated that CO exerts important biological
activities, including vasorelaxation, resolution of inflamma-
tory states, as well as anti-apoptotic and cytoprotective ac-
tions in various models of disease (26, 33). Binding of CO to
ferrous iron and other metal centers is thought to mediate
some of its biological effects; for example, in eukaryotic cells
CO at high concentrations targetsmitochondrial cytochrome c
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oxidase with an ensuing decrease in O2 consumption and
increased production of reactive oxygen species (ROS) (6, 13,
38, 46). On the other hand, small amounts of CO can either
induce preconditioning through ROS signaling (20) or de-
crease ROS generation by NADPH oxidase (39), thus playing
a role of arbiter in the process of cell survival and death (7, 5,
42). Since O2 and CO compete for the same active site in cy-
tochrome c oxidase and NADPH oxidase, the overall effect on
oxygen consumption and ROS production will depend
strictly on the intracellular concentrations of these two gases,
the type of cells and the conditions being considered (45, 18).
A recent fundamental advance in the field of CO research
has been the discovery of CO-releasing molecules (CO-RMs),
a group of chemicals that serve as carriers for the delivery of
controlled amounts of CO in biological systems (25, 9). These
molecules provide a useful pharmacological tool to exploit the
bioactive properties of CO and at the same time minimize the
inherent toxicity of this gas (17, 26, 24, 23). Numerous CO-
RMs have been recently developed possessing different che-
mical structure and properties as well as different rates of CO
release in cells and tissues (36, 15, 3, 19, 21). Essentially, two
major groups of CO-RMs have been extensively studied so
far: (i) metal carbonyls containing different types of transition
metals (26, 24); (ii) boranocarbonates that spontaneously re-
lease CO under physiological conditions (27, 1, 32).
In the past 3 years some unprecedented studies revealed
that CO and CO-RMs possess potent antimicrobial properties
(29, 11, 14, 28). This type of research is of paramount im-
portance because of the major public health problem posed
by the increased bacterial resistance to antibiotics currently
used to treat infections (16). Among transition metal carbon-
yls, the best characterized CO-RMs are the lipid-soluble
tricarbonyldichlororuthenium(II) dimer (CORM-2) and the
water-soluble tricarbonylchloro(glycinato)ruthenium(II) (Ru(CO)3
Cl(glycinate) [CORM-3]) (25, 9). In addition, sodium bor-
anocarbonate (CORM-A1) has been shown so far to be the
only nonmetal compound capable of releasing CO in aqueous
solutions (27). Davidge et al. showed that in Escherichia coli
under aerobic conditions CO liberated by CORM-3 binds to
the terminal oxidases of the respiratory electron transport
chain and inhibits the expression of genes involved in respi-
ration (11). Similarly, Nobre et al. demonstrated that CORM-2
and CORM-3 inhibit the growth of E. coli and Staphyloccocus
aureus under both aerobic and anaerobic conditions (29). In a
previous work, our group showed that CORM-3 is bacteri-
cidal in vitro against Pseudomonas aeruginosa by targeting the
respiratory electron transport chain (14). In addition, when
administered in vivo, CORM-3 improves the survival of mice
subjected to a lethal infection with P. aeruginosa (14). The re-
cently developed CO-RMs have been synthesized based on
the presence or absence of ametal center, the type of transition
metal being used, their solubility in water, and the coordi-
nation of ligands of different chemical nature that might
modulate the rate of CO release. Each one of these properties
may clearly contribute to the overall reactivity of CO liberated
by CO-RMs toward biological targets. Studying the compar-
ative effects of these different compounds should increase our
understanding on the mechanisms of action of CO-RMs on
cell function. The aim of the present work was to investigate
the effects of CO-RMs on bacterial oxygen consumption
and growth of P. aeruginosa. Specifically, we used two well-
characterized ruthenium-containing CO-RMs (CORM-2 and
CORM-3), which release CO with a fast kinetic and CORM-
A1, which lacks a metal center and liberates CO with a slow
rate. We then compared the effect of these CO-RMs in vitro
and in vivo with a newly synthesized CO-releaser,
[Me4N][Mn(CO)4(thioacetate)2] (CORM-371), which contains
manganese as transition metal but exhibits a slow kinetic of
CO release similar to CORM-A1.
Results
Detection of CO release from CO-RMs
The chemical structure of all CO-RMs used in this study are
shown in Figure 1. As a first step in studying the antimicrobial
action of different CO-RMs, we carefully examined the pattern
of CO release from these compounds using two different
techniques: the direct measurement of CO liberation with an
amperometric CO sensor (Fig. 2A, C) and the conversion of
deoxymyoglobin (deoxy-Mb) to carbonmonoxy myoglobin
(MbCO) (Fig. 2B, D). Depending on the CO-RM examined and
the method used for detecting CO release two patterns were
identified. On one hand, both the CO electrode (Fig. 2A) and
theMb-CO assay (Fig. 2B) showed that CORM-A1 (the boron-
FIG. 1. Chemical structure of CORM-2, CORM-3, CORM-
371, and CORM-A1. As shown, CORM-2 and CORM-3
contain a ruthenium center, CORM-371 is based on man-
ganese, and CORM-A1 does not contain any transition
metal. CORM-A1, sodium boranocarbonate; CORM-2,
tricarbonyldichlororuthenium(II) dimer; CORM-3, Ru(CO)3
Cl(glycinate); CORM-371, [Me4N][Mn(CO)4(thioacetate)2].
Innovation
CO-RMs have been originally designed as a tool to deliver
precise amounts of CO to cells and tissues to better under-
stand the signaling and physiological effects of this important
endogenous gas. Twomajor classes of CO-RMs have been so
far characterized and tested for their pharmacological prop-
erties: transition metal carbonyls and boranocarbonates. The
emerging chemical diversity, versatility, and reactivity of CO-
RMs with biological systems have clearly opened the possi-
bility of exploiting this novel class of compounds as potential
therapeutics. The study presented here reports on the com-
parative and differential antibacterial activities of these two
major classes of CO-RMs, highlighting the importance of
certain transition metal carbonyls in rendering CO more ef-
ficacious as bactericidal agent.
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based compound) and CORM 371 (the Mn-based compound)
liberated COwith a similar slow rate. The half-life for CORM-
A1 and CORM-371 calculated from the formation of Mb-CO
over time was 16.5 and 20.2min, respectively. On the other
hand, the Mb-CO assay confirmed that CORM-2 and CORM-
3, both ruthenium-based compounds, released COwith a very
fast rate (Fig. 2D), as previously published by our group (25, 9).
However, and of major interest, no CO was detected from
CORM-2 and CORM-3when using the CO electrode (Fig. 2C).
These results indicate that certain CO-RMs spontaneously re-
lease CO in solution, whereas others need an interaction with
biological components to trigger the release of CO (30).
Metal-containing CO-RMs but not CORM-A1 exert
persistent inhibition of bacterial growth
Based on previous data showing that CO mediated the
antibacterial effect of CORM-3 (14), we hypothesized that
differences in the rates of CO release could impact the effect of
different CO-RMs on bacterial growth. Interestingly, CORM-
2, CORM-3, and CORM-371 (10–500lM) inhibited bacterial
growth during a 20 h period with substantial inhibition ob-
served already at the lowest concentration examined ( p < 0.01
for each concentration vs. vehicle; Fig. 3A–C). Conversely, the
inhibition of bacterial growth by CORM-A1 (10–500 lM) was
reversible and the duration of this inhibition was concentra-
tion dependent. Treatment with CORM-A1 at 10, 100, and
500 lM delayed bacterial growth for 120, 240, and 470min,
respectively (Fig. 3D). Repeated additions of 100lM CORM-
A1 to the culture medium every 3 h during a 6 h period pro-
vided a longer inhibition of bacterial growth than a single
initial addition of 300lM, but bacterial growth inhibition was
still reversible (data not shown). In a previous study we
showed that the bactericidal effect of CORM-3 was mediated
by binding of CO to P. aeruginosa (PAO1) respiratory chain
(14). Thus, we analyzed the effect of CORM-2, CORM-3,
CORM-371, and CORM-A1 on PAO1 viability (Fig. 4A) and
oxygen (O2) consumption (Fig. 4B). These experiments re-
quired a high bacterial load (5 · 108 cfu/ml) to reach a level of
O2 consumption detectable by the electrode. The results ob-
tained from these experiments are very interesting and in-
formative. First, treatment with CORM-2 and CORM-3
(100lM) induced a similar and significant decrease in O2
consumption and a fast bactericidal effect with bacterial count
decreasing from 2· 106 to 0 within 3 h. Second, although
CORM-371 (100lM) decreased O2 consumption in a manner
similar to CORM-2 and CORM-3, bacterial count diminished
significantly after 2 h but stopped after 4 h. Third, CORM-A1
(100 lM) decreased O2 consumption only temporarily
reaching a steady state after 60min of treatment; moreover,
CORM-A1 did not diminish bacterial count. Collectively,
these data show that the metal-based CORM-2, CORM-3,
and CORM-371 produce a comparable inhibition of bacterial
growth and O2 consumption, but the manganese compound
(CORM-371) decreases bacterial count less potently than the
ones containing ruthenium. CORM-A1, which does not
contain a transition metal, elicits a decrease in O2 con-
sumption and bacterial growth that are less pronounced
than other CO-RMs and are only temporary. These results
suggest that the early inhibition of O2 consumption by CO
released fromCO-RMs is not the only factor influencing their
bactericidal effect.
FIG. 2. Detection of CO
release from CO-RMs: com-
parison between CO elec-
trode and myoglobin assay.
Left panels. Typical tracings
showing the current mea-
sured by an amperometric
CO sensor immersed in an
aqueous solution at 37C
upon addition of 100lM CO-
RMs. Note that while CO is
gradually detected over time
from CORM-A1 and CORM-
371 (A), no CO is measured
after addition of either
CORM-2 or CORM-3 (C).
Right panels. The amount of
MbCO formed over time at
37C was measured after ad-
dition of 50 lM CO-RMs to a
phosphate buffered solution
(pH 7.4) containing 50 lM
deoxymyoglobin. Note that
the rate of CO release from
CORM-A1 and CORM-371
(B) is similar (half-life at
20min) and much slower
compared with CORM-2 and
CORM-3 (D), which release
CO to myoglobin with a half-life of < 1min. Bars represents the mean– SEM of three experiments. CO, carbon monoxide; CO-
RMs, carbon monoxide-releasing molecules; MbCO, carbonmonoxy myoglobin; SEM, standard error of the mean.
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Effect of ROS production and N-acetylcysteine
on CO-RM-mediated bacterial growth
To investigate whether oxidative stress is involved in the
antibacterial effect mediated by CO-RMs, we measured the
oxidation of 2¢,7¢-dichlorofluorescin diacetate (DCFH-DA) as
an index of the production of ROS by PAO1 after treatment
with the various compounds. We found that none of the CO-
RMs changed ROS production after 30 or 60min (see Fig. 5),
confirming previous results obtained with CORM-3 (14). The
results also exclude oxidative stress as a potential mechanism
of bactericidal activity caused by CO-RMs. In the context of
oxidative stress, we have recently shown that N-acetylcysteine
(NAC) and other thiol compounds reverse the effect elicited
by CORM-3 on bacterial growth and O2 consumption (14),
leading us to hypothesize that NAC interferes with the in-
teraction of CO liberated fromCORM-3 and the cytochromes
of the bacterial respiratory chain. Since our present data
show that CO-RMs with different chemical properties dif-
ferentially influence bacterial growth and O2 consumption,
we examined the effect of NAC on the modification of bac-
terial growth induced by CORM-2, CORM-3, CORM-371
and CORM-A1. We found that NAC (1mM) completely in-
hibited the anti-bacterial effect of CORM-2 and CORM-3
(Fig. 6A, B), whereas its effect in the presence of CORM-371
was more complex. In fact, NAC did not inhibit bacterial
growth induced by 500 lM of CORM-371 but partially re-
versed the inhibition induced by 10 and 100 lM (Fig. 6C).
Finally, NAC did not modify CORM-A1-induced delay in
bacterial growth (Fig. 6D).
Concentrations of CO-RMs that are bactericidal
and anti-inflammatory do not cause toxicity
in eukaryotic cells
Having demonstrated that CO-RMs exert anti-bacterial
activities, we evaluated their anti-inflammatory and toxicity
profiles in eukaryotic cells at the concentrations that exhibit
bactericidal properties. As previously shown for CORM-2 and
CORM-3 (35, 37), we found that CORM-371 and CORM-A1 at
concentrations between 10 and 100 lM are not toxic to mac-
rophages as indicated by preserved cell viability (lactate de-
hydrogenase [LDH] release) after 24 h incubation (Fig. 7A).
Interestingly, whereas CORM-371 significantly decreased ni-
trite production in lipopolysaccharide (LPS)-stimualted mac-
rophages, CORM-A1 did not show any anti-inflammatory
effect (Fig. 7B, C). In addition, no significant cell toxicity was
detected in human lung fibroblasts from both smokers and
nonsmokers treated with 10–100 lM CO-RMs (Fig. 7D). Thus,
it appears that CO-RMs are not cytotoxic in murine and
human cells at the range of concentrations that exert anti-
A B
C D
FIG. 3. Effect of CO-RMs on Pseudomonas aeruginosa growth. Bacterial growth was followed for 20 h after treatment with
CO-RMs (10, 100 and 500lM) or vehicle and was assessed by measuring spectrophotometrically the optical density at
600 nm. The initial PAO1 inoculum was 4 · 106 cfu/ml. The vehicle used was sodium chloride 0.9% for the water-soluble
CORM-3 (A), CORM-371 (C), and CORM-A1 (D) and 0.1% DMSO for the lipid soluble CORM-2 (B). Curves represent means
of 6 independent experiments; error bars are omitted for clarity. *p < 0.05 versus vehicle. DMSO, dimethyl sulfoxide; PAO1,
Pseudomonas aeruginosa.
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bacterial action. Moreover, metal-containing CO-RMs are
more efficacious in their anti-inflammatory and anti-bacterial
activity in vitro than nonmetal CO-RMs. To provide readers
with a concise picture of the results collected in this study, we
summarized in Table 1 the characteristics of CO-RMs, their
rates of CO-release, and their effects on bacterial O2 con-
sumption and growth.
Effects of CO-RMs on bacterial infection in vivo
Among the three CO-RMs tested, only CORM-2 displayed
a significant efficacy in a model of bacterial infection. As
shown in Figure 8, administration of CORM-2 (25 lmol/kg)
significantly prolonged the survival of mice infected with
PAO1 at 24, 48, and 72 h (Fig. 8A), whereas CORM-371 was
without effect (Fig. 8B) and CORM-A1 worsen the survival
rate already at 24 h (Fig. 8C). These data support previous
results obtained by our group showing that another rutheni-
um-based carbonyl complex (CORM-3) exerts bactericidal
activity against P. aeruginosa and improves survival in an
animal model of bacteraemia (14).
Discussion
The results of the present study reveal a differential anti-
bacterial effect mediated by CO-RMs which depends on the
specific chemical nature of the compounds used. Indeed, the
CO-RMs tested not only exhibited a different chemical struc-
ture but were also selected based on the rate of CO release and
the presence or absence of specific transition metals. CORM-2
and CORM-3 contain ruthenium and are defined as fast CO
releasers since CO liberation occurs within 1min after their
addition to biological systems [present results and (25, 9, 24)].
These two compounds only differ by their solubility, in DMSO
for CORM-2 and in water for CORM-3. In contrast, CORM-A1
does not contain any transition metal but boron, and sponta-
neously releases CO in aqueous solution with a half-life of
approximately 21min under physiological conditions (37C,
pH 7.4) (27). In this study we also tested a new compound,
CORM-371, which is instrumental for comparison with the
others as it contains manganese (therefore falling into the
category of transition metal carbonyls) but releases CO with a
kinetic very similar to CORM-A1.We found that CORM-2 and
CORM-3 exerted inhibition of bacterial growth, which was
accompanied by an intense bactericidal effect and a persistent
decrease in O2 consumption. These findings confirm our pre-
viously published results on the antimicrobial effects of
CORM-3 on P. aeuroginosa (14) and reports by others on the
effects of CORM-2 and CORM-3 on E. coli and S. aureus (11,
29). We also observed an anti-bacterial activity of CORM-371
and CORM-A1, although with a different profile. CORM-A1
inhibited O2 consumption less profoundly than CORM-2 and
CORM-3 andonly delayed the initiation of bacterial growth. In
addition, CORM-A1 had no bactericidal properties but acted
more like a bacteriostatic agent. Interestingly, this effect is akin
to that elicited by CO gas as reported in a previous work
published by our group (14). Of note is that the novel
A
B
#
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FIG. 4. Effect of CO-RMs on bacterial count and oxygen
consumption. (A). Bacterial count on agar plate was mea-
sured every hour over a 6 h period after PAO1 strain (2 · 106
cfu/ml) was treated with 100 lM CORM-2, CORM-3,
CORM-371, or CORM-A1. *p< 0.05 versus bacterial count
before treatment (0 h line). Each curve represents the mean of
four independent experiments. (B). Oxygen consumption
measured over time during bacterial growth using a Clark
type oxygen electrode. PAO1 strain (5 · 108 cfu/ml) was
treated with 100 lM CORM-2, CORM-3, CORM-371, or
CORM-A1 (sodium chloride 0.9% was used as vehicle in the
control group). Measurements were performed at times 0, 10,
60, 90, 120, and 240min after treatment. Each curve repre-
sents the mean of four independent experiments. *p < 0.05
versus vehicle; #p< 0.05 versus CORM-A1.
FIG. 5. Production of H2O2 in PAO1 bacteria treated
with CO-RMs. The production of H2O2 in bacteria treated
with 100lM CORM-2, CORM-3, CORM-371, or CORM-A1
was measured fluorometrically after addition of 2¢-7¢-
dichlorodihydrofluorescein diacetate (see Materials and
Methods for details). Sodium chloride 0.9% (vehicle) and
DMSOwere used as negative control for CORM-3 and CORM-
2, respectively. Each bar represents the mean–SEM of six in-
dependent experiments. H2O2, hydrogen peroxide.
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manganese-containingCORM-371 is a slowCO releaserwith a
profile comparable to that of CORM-A1. However, the anti-
bacterial potency of CORM-371 was found to be intermediate
between the ruthenium-based compounds (CORM-2 and
CORM-3) and CORM-A1 since CORM-371 caused a profound
inhibition of O2 consumption and bacterial growth but exerted
a bactericidal effect less intense than CORM-2 or CORM-3.
Thus, the fact that CORM-371 and CORM-A1 have a sim-
ilar rate of CO release but CORM-A1 only exerts a bacterio-
static effect strongly suggests that the kinetic of CO liberation
from CO-RMs is not crucial to manifest their antibacterial
effects. Rather, combined with the results obtained with the
ruthenium based CORM-2 and CORM-3, which rapidly
abolished bacterial growth in vitro, it appears that the pres-
ence of a metal center and the nature of transition metal in
general play amore important role in the antibacterial activity
exerted by CO-RMs. In our precedent work, we established
that ruthenium per se did not posses any proper anti-bacterial
activity (14). However, our data suggest also that the nature of
the metal center cannot totally explain the effects of CO-RMs
on O2 consumption. Although we recently hypothesized that
the bactericidal effect of CORM-3wasmainly due to its ability
to decrease O2 consumption (14), the current expanded study
suggests otherwise. In fact, we found that the ruthenium-
based compounds and the manganese-based CORM-371
similarly decreased bacterial O2 consumption but differen-
tially affected bacterial count. Thus, the direct inhibition of
bacterial O2 consumption by CO-RMs does not justify the
antibacterial effect of these agents. This hypothesis is also
supported by previous works showing that both CORM-2
and CORM-3 inhibit the growth of E. coli under anaerobic
condition (11, 29). Other interesting mechanisms have been
proposed to explain the antibacterial effect of CO-RMs. Da-
vidge et al. showed that in E. coli treated with CORM-3 tran-
scriptor regulators other than the ones involved in O2
consumption or sensing (ArcA, CRP, Fis, FNR, Fur, BaeR,
CpxR, and IHF) could be a target of CO (11). Another report
provided data on a microarray analysis of E. coli treated with
CORM-2 and showed up-regulation of genes involved in
sulfur metabolism, such as tauABC, ssuAD, cysWA, and sbp,
and in methionine metabolism, like the gene clusters metNI
and metBLF (28). In the same study it was demonstrated that
E. coli mutants lacking genes involved in methionine biosyn-
thesis had an increased sensitivity to CORM-2. This particular
result suggests that the thiol-containing amino-acid methio-
nine could play a protective role in bacteria against the toxic
activities of CORM-2. This intriguing finding is in line with
the results of our previous work showing that supplementa-
tion of growth medium with thiol-containing NAC or re-
duced glutathione inhibited the antibacterial effect mediated
by CORM-3 but had no effect on the conversion of deoxy-Mb
to MbCO (14). In the present study we confirm that the anti-
A B
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FIG. 6. Effect of CO-RMs on PAO1 growth in the presence of NAC. Bacterial growth was followed for 20h after treatment
with CO-RMs (10, 100 and 500lM) or vehicle in the presence of 1mM NAC and was assessed by measuring spectrophoto-
metrically the optical density at 600nm. Initial PAO1 inoculum was 4·106 cfu/ml. The vehicle used was sodium chloride 0.9%
for the water-soluble CORM-3 (A), CORM-371 (C), and CORM-A1 (D) and 0.1% DMSO for the lipid soluble CORM-2 (B). Curves
represent means of six independent experiments; error bars are omitted for clarity. *p<0.05 versus vehicle. NAC,N-acetylcysteine.
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bacterial effects of metal-containing CO-RMs (CORM-2,
CORM-3, and CORM-371) but not CORM-A1 was reversed
by the presence of NAC in the growth medium. These data
point toward an interplay between the metal center of a given
CO-RM, the inhibitory capacities of metal carbonyls on bac-
terial growth and the presence of thiol-containing aminoacids
in bacteria. Although little is known about the role of thiols in
bacterial targets that are responsive to CO, the importance of
cysteine residues in modulating a thiol/disulfide redox
switch that controls the affinity of heme and CO for large
conductance calcium-activated potassium channels (BKCa)
has recently been proposed (44). Apart from altering the in-
teraction of sensitive cysteines with iron-heme centers, the
presence of high concentrations of thiols as in our experi-
mental setting may favor a very rapid release of CO from
transition-metal carbonyls, thus preventing the gas to reach
the intracellular milieu and evoke its effect intracellularly (19).
Nevertheless, the nature of this important interplay between
intracellular and extracellular thiols and CO in their interac-
tion with critical metal centers in functional proteins sensitive
to CO deserves further deep investigation.
Thus, the results presented here strongly suggest that the
rate of CO liberation by CO-RMs is not the only component
affecting the growth of Pseudomonas, but a more important
role is played by the metal center in maximizing the anti-
bacterial effect of CO. We emphasize that ruthenium-based
compounds (CORM-2 and CORM-3), which similarly affect
bacterial growth, cell viability, and O2 consumption, elicit a
very fast carbonylation of myoglobin, but no CO release is
detected using a CO electrode. This suggests either a direct
transfer of CO from CO-RM to its potential target and/or the
need of specific aminoacid in proteins (in this case myoglo-
bin), which favors the liberation of CO. We did not observe
any toxicity of CORM-371 and CORM-A1 against eukaryotic
cells and this is in line with previous works showing similar
results using CORM-2 and CORM-3 (14, 37). The high sensi-
tivity of P. aeruginosa toward CO-RMs as compared with
macrophages may be due to a greater accessibility of CO to
targets in bacteria. The data obtained in vivo provide more
instructive information as among the CO-RMs tested only
CORM-2was significantly effective in prolonging the survival
rate of mice infected with P. aeruginosa. First of all, this is in
line with previous results showing that CORM-2 reduces
endotoxemia and increases survival in infected HO-1-defi-
cient mice (40). Moreover, our present results supports our
previous findings on the in vivo antibacterial effects of CORM-
FIG. 7. Cytotoxicity and anti-inflammatory profiles of CORM-A1 and CORM-371 in RAW 264.7 macrophages and
human lung fibroblasts. (A) LDH, an index of cell injury, was measured in the medium after treating macrophages for 24 h
with CORM-A1 (black bars) or CORM-371 (gray bars). Cells were incubated for 24 h with CO-RMs (0–100 lM). The data (n = 6)
are expressed as a percentage of cell toxicity caused by triton (1%) (positive control). *p< 0.05 versus control; B and C. Nitrite
production in macrophages challenged for 24 h with 1lg/ml LPS alone or LPS in the presence of CORM-371 (B) or CORM-
A1 (C). Bars represent the mean of six independent experiments (mean – SEM). *p< 0.05 versus no treatment (control); #p< 0.05
versus LPS. (D) Cytotoxicity (MTT assay) in human lung fibroblasts collected from healthy subjects and smokers was
measured in cells treated for 24 h with CO-RMs (0–100 lM). The data (n = 6) are expressed as % of control (100% viability).
LDH, lactate dehydrogenase; LPS, lipopolysaccharide.
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3 (14), which profile of CO release is the same as CORM-2
when tested with the CO electrode and the myoglobin assay.
We must remember that in vivo both CORM-2 and CORM-3
do not lead to an increase in carbonmonoxy hemoglobin but
their ability to transfer COmore effectively to targeted tissues
and elicit a pharmacological effect toward a given patholog-
ical state is now supported by several studies using in vivo
models of disease (41, 22, 12, 42). In the case of CORM-2,
liposolubility of this compound may also affect its efficacy
compared with the water-soluble CORM-A1 and CORM-371
(3716, 4189). Thus, the fact that CORM-2 is the only CO-RM to
be effective in vivo against bacterial infection indicate that the
specific design of CO-RMs capable of transferring CO directly
to a target within a cell (trans-carbonylation) may lead to more
effective therapeutic agents based on CO delivery in mam-
mals. In addition, the type of metal that carries CO to the
target may also be crucial in eliciting a specific biological ac-
tion. Indeed, it is interesting to note that terpyridine rutheni-
um(II) complexes have been shown to exhibit a very good
activity against P. aeruginosa and other pathogens (4) indi-
cating that a concerted action between this metal and CO in
the bactericidal effect of CORM-2 and CORM-3 observed
in vivo cannot be excluded a priori.
In conclusion, we report here that certain transition metal
carbonyls are effective in suppressing P. aeruginosa growth
and could represent an interesting new chemical scaffold in
anti-infective research. This study is the first to indicate that
the anti-microbial activities of CO-RMs, particularly CORM-2
and CORM-3, cannot be explained solely by their CO releas-
ing properties since the effects are mediated by a complex
network involving CO liberation, the presence of a metal
center that favors CO targeting bacteria and the interaction
between CO-RMs and their intracellular target(s).
Materials and Methods
Reagents
NAC was obtained from Sigma-Aldrich. DCFH-DA was
obtained from Molecular Probes. CORM-2 was purchased
from Sigma Aldrich. CORM-3 and Na[H3BCO2H] or CORM-
A1 were synthesized as previously described (9, 27). The
novel manganese-containing compound, CORM-371, was
prepared as reported below.
Preparation of CORM-371
One hundred fifty milligrams (0.436 mmol) of Mn(CO)5
(SO3CF3) (12) and 128mg (0.857mmol) of [Me4N][thioacetate]
Table 1. Chemical Features of Carbon Monoxide-Releasing Molecules, Their Rates of Carbon Monoxide-Release
Measured with Two Different Assays and Their Effects on Bacterial O2 Consumption and Growth
Rate of CO release
Compound
Metal
center
CO
electrode
Myoglobin
assay
O2
consumption
Bacterial
growth
Bacterial
count
Effect of
N-acetylcysteine
CORM-2 Ruthenium Not detected Fast Profound decrease Inhibition Total decrease Total
CORM-3 Ruthenium Not detected Fast Profound decrease Inhibition Total decrease Total
CORM-371 Manganese Slow Slow Profound decrease Inhibition Partial decrease Partial
CORM-A1 None Slow Slow Mild decrease Transient
inhibition
No decrease None
A
B
C
FIG. 8. In vivo effects of CO-RMs against PAO1 bacterial
infection. Kaplan–Meier curves representing the survival of
BALB/c mice subjected to PAO1 bacteremia. Five minutes
after bacterial challenge, mice (n= 6 per group) were treated
with a single intraperitoneal injection of 25lmol/kg CORM-
2 (A), CORM-371 (B), or CORM-A1 (C). Control groups
received vehicle that was either saline in case of the water-
soluble CORM-371 and CORM-A1 or DMSO (1%) in the case
of CORM-2. Survival rate was evaluated every 24 h. Log-
rank test. *p< 0.05 versus vehicle group.
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were stirred in 8ml of dry tetrahydrofurane and 2ml of
methanol, under argon at 50–55C for 4.5–5 h. During this
time the color of the solution went a little darker yellow/
orange. After this, the solvent was removed on rotary evap-
orator to give a yellow/orange semi-solid residue. This was
crystallized from dichloromethane/diethyl ether at - 18C to
give 91mg of a yellow crystalline product (yield = 55.7%).
Bacterial strain and growth conditions
P. aeruginosa (PAO1, American Tissue Culture Collection
15692) was grown aerobically for 24 h at 37C in Luria-Bertani
(LB) medium and then washed twice in NaCl 0.9% before the
experiments. The procedures of growth were the same as
previously published by our group (14). Experiments were
performed aerobically at 37C in minimal M9 medium
(Na2HPO4 6 g/l, KH2PO4 3 g/l, NaCl 0.5 g/l, NH4Cl 1 g/l,
and MgSO4.7H2O 0.25 g/l) containing 2 g/l glucose. We used
an initial bacterial concentration of 4 · 106 cfu/ml. PAO1
growth was determined by measuring the optical density at
600 nm each 10min for 20 h in 96-well plates using 300ll of
medium for each condition. The number of viable cells (bac-
terial count) was evaluated by measuring the colony-forming
unit (cfu/ml) after plating serial dilutions of the various cul-
tures onto LB agar plates. CO-RMs were added to the growth
medium at the concentrations indicated and viability assessed
at different times of growth.
Measurement of oxygen consumption
Oxygen consumption was measured at 37C under agita-
tion using aClark-type electrode (14). Bacteria (5· 108 cfu/ml)
were incubated in 1ml of a respiration buffer containing
100mM KCl, 50mM sucrose, 10mM HEPES, and 5mM
KH2PO4, pH 7.4, at 37C. Respiration was initiated by addi-
tion of glucose (2 g/l).
Measurement of ROS production
by the DCFH-DA assay
The formation of ROS was measured by oxidation of
DCFH-DA into 2¢,7¢-dichlorofluorescin (DCF). Bacteria were
incubated for 60minwith 20lMDCFH-DA, then centrifuged,
and washed twice in Hanks’ balanced salt solution (HBSS).
Bacteria (2 · 107cfu/ml) re-suspended in HBSS were treated
with the different CO-RMs (100 lM) or vehicle. ROS produced
in bacteria lead to oxidation of DCFH, yielding the fluorescent
product DCF measured fluorometrically at 520 nm after ex-
citation at 480 nm (34).
Detection of CO release from CO-RMs using
a myoglobin assay
The release of CO from CO-RMs was assessed spectro-
photometrically by measuring the conversion of deoxy-Mb to
MbCO as previously reported (25, 9). A small aliquot of
concentrated CO-RM solution was added to 1ml deoxy-Mb
solution in phosphate buffer (final concentrations: CO-RM =
50lM; deoxy-Mb = 53 lM), and changes in the Mb spectra
were recorded over time. The amount of MbCO formed was
quantified by measuring the absorbance at 540 nm. Before the
addition of CO-RMs, 500 ll of mineral oil (SigmaAldrich) was
added on top of the aqueous solution containing Mb to pre-
vent CO escaping and the myoglobin becoming oxygenated.
Detection of CO release from CO-RMs using
an amperometric CO sensor
The spontaneous release of CO from the selected CO-RMs
was measured using a CO-sensitive electrode as previously
described (27). This CO electrode (World Precision Instrument)
is a membrane-covered amperometric sensor that has been
designed on a basic operating principle similar to the nitric
oxide (NO) sensor. The CO sensor can be connected to theWPI
ISO-NO Mark II meter for detection of the current signals
providing that the poise potential is set to a different value
(900mV for CO as opposed to 860mV for NO). Briefly, CO
diffuses through the gas permeable membrane and is then ox-
idized to CO2 on the working electrode. This oxidation will
create a current whose magnitude can be related directly to the
concentration of CO in solution. The electrode was immersed
into distilledwater containing 0.1Mphosphate buffer (pH= 7.4)
and equilibrated for 30min before addition of CO-RMs
(100lM). The experiments were conducted at 37C and the
solutions were maintained at the desired temperature using a
Grant W6 thermostat.
Assessment of cell viability
Murine RAW264.7 monocyte macrophages were purchased
from the European Collection of Cell Cultures (Salisbury) and
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 2mM L-glutamine, 100
units ml- 1 penicillin, and 0.1mg ml- 1 streptomycin. Cultures
were maintained at 37C in a 5% CO2 humidified atmosphere
and experiments were conducted on cells at approximately
80%–90% confluence. Macrophages were exposed for 24h to
different concentrations of CO-RMs and LDH activity was
measured as an index of cell damage using a commercially
available assay kit (Roche) according to manufacturer’s in-
structions. Human lung fibroblasts were collected and cultured
as previously described (2). Cellswere also exposed to different
concentrations of CO-RMs for 24h and anMTT assaywas used
at the end to assess the extent of cytotoxicity.
Nitrite assay
Nitrite production in macrophages stimulated with LPS
was determined using the Griess method (35). The measure-
ment of this parameter is indicative of NO production and
widely accepted as a marker of inflammation. Macrophages
were exposed to LPS (1lg/ml) for 24h in the presence or
absence of CO-RMs (10, 50, and 100lM) and nitrite levelswere
determined at the end of the incubation. Briefly, the medium
from treated cells cultured in 24-well plates was removed and
placed into a 96-well plate (50ll per well). The Griess reagent
was added to each well to begin the reaction, the plate was
shaken for 10min, and the absorbance read at 550 nm on a
MolecularDevices VERSAmax plate reader. The nitrite level in
each sample was calculated from a standard curve generated
with sodium nitrite (0–300lM in cell culture medium).
In vivo model of bacterial infection
A mouse model of bacterial infection was used as previ-
ously described by us (14). Briefly, bacteremia was obtained
by an intraperitoneal injection of 2· 107 bacteria (PAO1) in
BALB/c mice (7 to 8 weeks old, 20 to 25 g from Janvier). Mice
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were then treated with 25lmol/kg CO-RM or vehicle ad-
ministered intraperitoneally 5min after bacterial challenge.
The dose of for each CO-RM was selected in agreement with
previous in vivo studies showing a therapeutic effect of
CORM-3 (14). The survival rate was evaluated every 24 h.
Statistical analysis
Data are expressed as mean– standard error of the mean. For
comparisons between two groups, we used two-tailed non-
parametric Mann–Whitney U analysis. For comparison among
more than two groups and multiple comparisons, we used the
nonparametric Kruskal–Wallis test with the Dunn’s post test.
The number of samples per group (n) is specified in Results or in
the figure legend. Statistical significancewas accepted at p<0.05.
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CO¼ carbon monoxide
CO-RMs¼ carbon monoxide-releasing molecules
CORM-A1¼ sodium boranocarbonate
CORM-2¼ tricarbonyldichlororuthenium(II) dimer
CORM-3¼Ru(CO)3Cl(glycinate)
CORM-371¼ [Me4N][Mn(CO)4(thioacetate)2]
DCFH-DA¼ 2¢-7¢-dichlorodihydrofluorescein diacetate
deoxy-Mb¼deoxymyoglobin
DMSO¼dimethyl sulfoxide
H2O2¼hydrogen peroxide
LB¼Luria-Bertani medium
LDH¼ lactate dehydrogenase
LPS¼ lipopolysaccharide
MbCO¼ carbonmonoxy myoglobin
NAC¼N-acetylcysteine
NO¼nitric oxide
PAO1¼Pseudomonas aeruginosa
ROS¼ reactive oxygen species
SEM¼ standard error of the mean
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